Non-Contrast-Enhancing Tumor: A New Frontier in Glioblastoma Research

REFERENCES

1. 1.↵
   2. Louis DN,
   3. Ohgaki H,
   4. Wiestler OD, et al

   . World Health Organization Histological Classification of Tumors of the Central Nervous System. Lyon: International Agency for Research on Cancer; 2016
2. 2.↵
   2. Yan H,
   3. Parsons DW,
   4. Jin G, et al

   . IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765–73 doi:10.1056/NEJMoa0808710 pmid:19228619

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Weller M,
   3. van den Bent M,
   4. Tonn JC, et al

   ; European Association for Neuro-Oncology (EANO) Task Force on Gliomas. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol 2017;18:e315–29 doi:10.1016/S1470-2045(17)30194-8 pmid:28483413

   CrossRefPubMed
4. 4.↵
   2. Karachaliou N,
   3. Gonzalez-Cao M,
   4. Sosa A, et al

   . The combination of checkpoint immunotherapy and targeted therapy in cancer. Ann Transl Med 2017;5:388 doi:10.21037/atm.2017.06.47 pmid:29114546

   CrossRefPubMed
5. 5.↵
   2. Lee YT,
   3. Tan YJ,
   4. Oon CE

   . Molecular targeted therapy: treating cancer with specificity. Eur J Pharmacol 2018;834:188–96 doi:10.1016/j.ejphar.2018.07.034 pmid:30031797

   CrossRefPubMed
6. 6.↵
   2. Hardesty DA,
   3. Sanai N

   . The value of glioma extent of resection in the modern neurosurgical era. Front Neurol 2012;3:140 doi:10.3389/fneur.2012.00140 pmid:23087667

   CrossRefPubMed
7. 7.↵
   2. Lacroix M,
   3. Abi-Said D,
   4. Fourney DR, et al

   . A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001;95:190–98 doi:10.3171/jns.2001.95.2.0190 pmid:11780887

   CrossRefPubMedWeb of Science
8. 8.↵
   2. Stummer W,
   3. Reulen HJ,
   4. Meinel T, et al

   ; ALA-Glioma Study Group. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 2008;62:564–76; discussion 564–76 doi:10.1227/01.neu.0000317304.31579.17 pmid:18425006

   CrossRefPubMedWeb of Science
9. 9.↵
   2. Chamberlain MC

   . Radiographic patterns of relapse in glioblastoma. J Neurooncol 2011;101:319–23 doi:10.1007/s11060-010-0251-4 pmid:21052776

   CrossRefPubMed
10. 10.↵
    2. Kubben PL,
    3. ter Meulen KJ,
    4. Schijns OE, et al

    . Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic review. Lancet Oncol 2011;12:1062–70 doi:10.1016/S1470-2045(11)70130-9 pmid:21868286

    CrossRefPubMedWeb of Science
11. 11.↵
    2. Schulz C,
    3. Waldeck S,
    4. Mauer UM

    . Intraoperative image guidance in neurosurgery: development, current indications, and future trends. Radiol Res Pract 2012;2012:197364 doi:10.1155/2012/197364 pmid:22655196

    CrossRefPubMed
12. 12.↵
    2. Zhao S,
    3. Wu J,
    4. Wang C, et al

    . Intraoperative fluorescence-guided resection of high-grade malignant gliomas using 5-aminolevulinic acid-induced porphyrins: a systematic review and meta-analysis of prospective studies. PLoS One 2013;8:e63682 doi:10.1371/journal.pone.0063682 pmid:23723993

    CrossRefPubMed
13. 13.↵
    2. Lasocki A,
    3. Gaillard F,
    4. Tacey MA, et al

    . The incidence and significance of multicentric noncontrast-enhancing lesions distant from a histologically-proven glioblastoma. J Neurooncol 2016;129:471–78 doi:10.1007/s11060-016-2193-y pmid:27412000

    CrossRefPubMed
14. 14.↵
    2. Eidel O,
    3. Burth S,
    4. Neumann JO, et al

    . Tumor infiltration in enhancing and non-enhancing parts of glioblastoma: a correlation with histopathology. PLoS One 2017;12:e0169292 doi:10.1371/journal.pone.0169292 pmid:28103256

    CrossRefPubMed
15. 15.↵
    2. Jain R,
    3. Poisson LM,
    4. Gutman D, et al

    . Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor. Radiology 2014;272:484–93 doi:10.1148/radiol.14131691 pmid:24646147

    CrossRefPubMed
16. 16.↵
    2. Lasocki A,
    3. Gaillard F,
    4. Tacey M, et al

    . Incidence and prognostic significance of non-enhancing cortical signal abnormality in glioblastoma. J Med Imaging Radiat Oncol 2016;60:66–73 doi:10.1111/1754-9485.12421 pmid:26597591

    CrossRefPubMed
17. 17.↵
    2. Grabowski MM,
    3. Recinos PF,
    4. Nowacki AS, et al

    . Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J Neurosurg 2014;121:1115–23 doi:10.3171/2014.7.JNS132449 pmid:25192475

    CrossRefPubMedWeb of Science
18. 18.↵
    2. Kotrotsou A,
    3. Elakkad A,
    4. Sun J, et al

    . Multi-center study finds postoperative residual non-enhancing component of glioblastoma as a new determinant of patient outcome. J Neurooncol 2018;139:125–33 doi:10.1007/s11060-018-2850-4 pmid:29619649

    CrossRefPubMed
19. 19.↵
    2. Carrillo JA,
    3. Lai A,
    4. Nghiemphu PL, et al

    . Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol 2012;33:1349–55 doi:10.3174/ajnr.A2950 pmid:22322613

    Abstract/FREE Full Text
20. 20.↵
    2. Lasocki A,
    3. Tsui A,
    4. Gaillard F, et al

    . Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma. J Clin Neurosci 2017;39:170–75 doi:10.1016/j.jocn.2017.01.007 pmid:28214089

    CrossRefPubMed
21. 21.↵
    2. Hygino da Cruz LC Jr.,
    3. Rodriguez I,
    4. Domingues RC, et al

    . Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 2011;32:1978–85 doi:10.3174/ajnr.A2397 pmid:21393407

    Abstract/FREE Full Text
22. 22.↵
    2. Wen PY,
    3. Macdonald DR,
    4. Reardon DA, et al

    . Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J Clin Oncol 2010;28:1963–72 doi:10.1200/JCO.2009.26.3541 pmid:20231676

    Abstract/FREE Full Text
23. 23.↵
    2. Boxerman JL,
    3. Zhang Z,
    4. Safriel Y, et al

    . Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686. Neuro Oncol 2018;20:1400–10 doi:10.1093/neuonc/noy049 pmid:29590461

    CrossRefPubMed
24. 24.↵
    2. Huang RY,
    3. Rahman R,
    4. Ballman KV, et al

    . The impact of T2/FLAIR evaluation per RANO criteria on response assessment of recurrent glioblastoma patients treated with bevacizumab. Clin Cancer Res 2016;22:575–81 doi:10.1158/1078-0432.CCR-14-3040 pmid:26490307

    Abstract/FREE Full Text
25. 25.↵
    2. Nowosielski M,
    3. Wiestler B,
    4. Goebel G, et al

    . Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. Neurology 2014;82:1684–92 doi:10.1212/WNL.0000000000000402 pmid:24727314

    CrossRefPubMed
26. 26.↵
    2. Yordanova YN,
    3. Moritz-Gasser S,
    4. Duffau H

    . Awake surgery for WHO grade II gliomas within “noneloquent” areas in the left dominant hemisphere: toward a “supratotal” resection: clinical article. J Neurosurg 2011;115:232–39 doi:10.3171/2011.3.JNS101333 pmid:21548750

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Li YM,
    3. Suki D,
    4. Hess K, et al

    . The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection? J Neurosurg 2016;124:977–88 doi:10.3171/2015.5.JNS142087 pmid:26495941

    CrossRefPubMed
28. 28.↵
    2. Pessina F,
    3. Navarria P,
    4. Cozzi L, et al

    . Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience. J Neurooncol 2017;135:129–39 doi:10.1007/s11060-017-2559-9 pmid:28689368

    CrossRefPubMed
29. 29.↵
    2. Beiko J,
    3. Suki D,
    4. Hess KR, et al

    . IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol 2014;16:81–91 doi:10.1093/neuonc/not159 pmid:24305719

    CrossRefPubMed
30. 30.↵
    2. Pope WB,
    3. Sayre J,
    4. Perlina A, et al

    . MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 2005;26:2466–74 pmid:16286386

    Abstract/FREE Full Text
31. 31.↵
    2. Lasocki A,
    3. Gaillard F,
    4. Tacey M, et al

    . Morphologic patterns of noncontrast-enhancing tumor in glioblastoma correlate with IDH1 mutation status and patient survival. J Clin Neurosci 2018;47:168–73 doi:10.1016/j.jocn.2017.09.007 pmid:28988652

    CrossRefPubMed
32. 32.↵
    2. Baldock AL,
    3. Ahn S,
    4. Rockne R, et al

    . Patient-specific metrics of invasiveness reveal significant prognostic benefit of resection in a predictable subset of gliomas. PLoS One 2014;9:e99057 doi:10.1371/journal.pone.0099057 pmid:25350742

    CrossRefPubMed
33. 33.↵
    2. Stupp R,
    3. Mason WP,
    4. van den Bent MJ, et al

    ; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96 doi:10.1056/NEJMoa043330 pmid:15758009

    CrossRefPubMedWeb of Science
34. 34.↵
    2. Duma CM,
    3. Kim BS,
    4. Chen PV, et al

    . Upfront boost gamma knife “leading-edge” radiosurgery to FLAIR MRI-defined tumor migration pathways in 174 patients with glioblastoma multiforme: a 15-year assessment of a novel therapy. J Neurosurg 2016;125(Suppl 1):40–49 doi:10.3171/2016.7.GKS161460 pmid:27903197

    CrossRefPubMed
35. 35.↵
    Wiki for the VASARI feature set. The National Cancer Institute. 2015. https://wiki.cancerimagingarchive.net/display/Public/VASARI+Research+Project. Accessed November 22, 2018.
36. 36.↵
    2. Muccio CF,
    3. Tarantino A,
    4. Esposito G, et al

    . Differential diagnosis by unenhanced FLAIR T2-weighted magnetic resonance images between solitary high grade gliomas and cerebral metastases appearing as contrast-enhancing cortico-subcortical lesions. J Neurooncol 2011;103:713–17 doi:10.1007/s11060-010-0454-8 pmid:21069426

    CrossRefPubMed
37. 37.↵
    2. Stuckey SL,
    3. Wijedeera R

    . Multicentric/multifocal cerebral lesions: can fluid-attenuated inversion recovery aid the differentiation between glioma and metastases? J Med Imaging Radiat Oncol 2008;52:134–39 doi:10.1111/j.1440-1673.2008.01931.x pmid:18373804

    CrossRefPubMed
38. 38.↵
    2. Tang YM,
    3. Ngai S,
    4. Stuckey S

    . The solitary enhancing cerebral lesion: can FLAIR aid the differentiation between glioma and metastasis? AJNR Am J Neuroradiol 2006;27:609–11 pmid:16552003

    Abstract/FREE Full Text
39. 39.↵
    2. Chang PD,
    3. Malone HR,
    4. Bowden SG, et al

    . A multiparametric model for mapping cellularity in glioblastoma using radiographically localized biopsies. AJNR Am J Neuroradiol 2017;38:890–98 doi:10.3174/ajnr.A5112 pmid:28255030

    Abstract/FREE Full Text
40. 40.↵
    2. Lasocki A,
    3. Gaillard F,
    4. Tacey M, et al

    . Multifocal and multicentric glioblastoma: improved characterisation with FLAIR imaging and prognostic implications. J Clin Neurosci 2016;31:92–98 doi:10.1016/j.jocn.2016.02.022 pmid:27343042

    CrossRefPubMed
41. 41.↵
    2. Brandão LA,
    3. Shiroishi MS,
    4. Law M

    . Brain tumors: a multimodality approach with diffusion-weighted imaging, diffusion tensor imaging, magnetic resonance spectroscopy, dynamic susceptibility contrast and dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging Clin N Am 2013;21:199–239 doi:10.1016/j.mric.2013.02.003 pmid:23642551

    CrossRefPubMed
42. 42.↵
    2. Guo AC,
    3. Cummings TJ,
    4. Dash RC, et al

    . Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology 2002;224:177–83 doi:10.1148/radiol.2241010637 pmid:12091680

    CrossRefPubMedWeb of Science
43. 43.↵
    2. Kono K,
    3. Inoue Y,
    4. Nakayama K, et al

    . The role of diffusion-weighted imaging in patients with brain tumors. AJNR Am J Neuroradiol 2001;22:1081–88 pmid:11415902

    Abstract/FREE Full Text
44. 44.↵
    2. Tien RD,
    3. Felsberg GJ,
    4. Friedman H, et al

    . MR imaging of high-grade cerebral gliomas: value of diffusion-weighted echoplanar pulse sequences. AJR Am J Roentgenol 1994;162:671–77 doi:10.2214/ajr.162.3.8109520 pmid:8109520

    CrossRefPubMedWeb of Science
45. 45.↵
    2. Castillo M,
    3. Smith JK,
    4. Kwock L, et al

    . Apparent diffusion coefficients in the evaluation of high-grade cerebral gliomas. AJNR Am J Neuroradiol 2001;22:60–64 pmid:11158889

    Abstract/FREE Full Text
46. 46.↵
    2. Holodny AI,
    3. Makeyev S,
    4. Beattie BJ, et al

    . Apparent diffusion coefficient of glial neoplasms: correlation with fluorodeoxyglucose-positron-emission tomography and gadolinium-enhanced MR imaging. AJNR Am J Neuroradiol 2010;31:1042–48 doi:10.3174/ajnr.A1989 pmid:20150307

    Abstract/FREE Full Text
47. 47.↵
    2. Price SJ,
    3. Jena R,
    4. Burnet NG, et al

    . Improved delineation of glioma margins and regions of infiltration with the use of diffusion tensor imaging: an image-guided biopsy study. AJNR Am J Neuroradiol 2006;27:1969–74 pmid:17032877

    Abstract/FREE Full Text
48. 48.↵
    2. Stadlbauer A,
    3. Ganslandt O,
    4. Buslei R, et al

    . Gliomas: histopathologic evaluation of changes in directionality and magnitude of water diffusion at diffusion-tensor MR imaging. Radiology 2006;240:803–10 doi:10.1148/radiol.2403050937 pmid:16926329

    CrossRefPubMedWeb of Science
49. 49.↵
    2. Ellingson BM,
    3. Malkin MG,
    4. Rand SD, et al

    . Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging 2010;31:538–48 doi:10.1002/jmri.22068 pmid:20187195

    CrossRefPubMedWeb of Science
50. 50.↵
    2. Zeng Q,
    3. Ling C,
    4. Shi F, et al

    . Glioma infiltration sign on high b-value diffusion-weighted imaging in gliomas and its prognostic value. J Magn Reson Imaging 2018 Mar 1. [Epub ahead of print] doi:10.1002/jmri.25986 pmid:29498144

    CrossRefPubMed
51. 51.↵
    2. Price SJ,
    3. Green HA,
    4. Dean AF, et al

    . Correlation of MR relative cerebral blood volume measurements with cellular density and proliferation in high-grade gliomas: an image-guided biopsy study. AJNR Am J Neuroradiol 2011;32:501–06 doi:10.3174/ajnr.A2312 pmid:21163880

    Abstract/FREE Full Text
52. 52.↵
    2. Sadeghi N,
    3. D'Haene N,
    4. Decaestecker C, et al

    . Apparent diffusion coefficient and cerebral blood volume in brain gliomas: relation to tumor cell density and tumor microvessel density based on stereotactic biopsies. AJNR Am J Neuroradiol 2008;29:476–82 doi:10.3174/ajnr.A0851 pmid:18079184

    Abstract/FREE Full Text
53. 53.↵
    2. Gupta A,
    3. Young RJ,
    4. Karimi S, et al

    . Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma. AJNR Am J Neuroradiol 2011;32:1301–06 doi:10.3174/ajnr.A2479 pmid:21596805

    Abstract/FREE Full Text
54. 54.↵
    2. Danchaivijitr N,
    3. Waldman AD,
    4. Tozer DJ, et al

    . Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation? Radiology 2008;247:170–78 doi:10.1148/radiol.2471062089 pmid:18372467

    CrossRefPubMed
55. 55.↵
    2. Stadlbauer A,
    3. Gruber S,
    4. Nimsky C, et al

    . Preoperative grading of gliomas by using metabolite quantification with high-spatial-resolution proton MR spectroscopic imaging. Radiology 2006;238:958–69 doi:10.1148/radiol.2382041896 pmid:16424238

    CrossRefPubMedWeb of Science
56. 56.↵
    2. Castillo M,
    3. Smith JK,
    4. Kwock L

    . Correlation of myo-inositol levels and grading of cerebral astrocytomas. AJNR Am J Neuroradiol 2000;21:1645–49 pmid:11039343

    Abstract/FREE Full Text
57. 57.↵
    2. Nowosielski M,
    3. DiFranco MD,
    4. Putzer D, et al

    . An intra-individual comparison of MRI, [18F]-FET and [18F]-FLT PET in patients with high-grade gliomas. PLoS One 2014;9:e95830 doi:10.1371/journal.pone.0095830 pmid:24759867

    CrossRefPubMed
58. 58.↵
    2. Lopez WO,
    3. Cordeiro JG,
    4. Albicker U, et al

    . Correlation of (18)F-fluoroethyl tyrosine positron-emission tomography uptake values and histomorphological findings by stereotactic serial biopsy in newly diagnosed brain tumors using a refined software tool. Onco Targets Ther 2015;8:3803–15 doi:10.2147/OTT.S87126 pmid:26719708

    CrossRefPubMed
59. 59.↵
    2. Artzi M,
    3. Liberman G,
    4. Blumenthal DT, et al

    . Differentiation between vasogenic edema and infiltrative tumor in patients with high-grade gliomas using texture patch-based analysis. J Magn Reson Imaging 2018 Jan 3. [Epub ahead of print] doi:10.1002/jmri.25939 pmid:29314345

    CrossRefPubMed
60. 60.↵
    2. Hu LS,
    3. Ning S,
    4. Eschbacher JM, et al

    . Multi-parametric MRI and texture analysis to visualize spatial histologic heterogeneity and tumor extent in glioblastoma. PLoS One 2015;10:e0141506 doi:10.1371/journal.pone.0141506 pmid:26599106

    CrossRefPubMed